Get started
Author

Jesse S. Siffledeen

Observed names: J S Siffledeen, J Siffledeen, J. Siffledeen, Jesse S Siffledeen, Jesse Siffledeen, Siffledeen, Jesse
Observed institutions: University of Alberta, Grey Nuns Community Hospital, Covenant Health, John Radcliffe Hospital, University of Alberta Hospital, Crohn's and Colitis Canada, University of Oxford, Centre Hospitalier Régional et Universitaire de Nancy
OpenAlex ID: A5007960255
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
2022 · Silvio Danese, Séverine Vermeire, et al. · The Lancet · 647
PDF
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
2020 · William J. Sandborn, Subrata Ghosh, et al. · Gastroenterology · 290
PDF
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
2021 · Brian Bressler, Andres Yarur, et al. · Journal of Crohn s and Colitis · 148
PDF
Risankizumab for Ulcerative Colitis
2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 134
PDF
Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy
2012 · Natasha S. Stephens, Jesse Siffledeen, et al. · Journal of Crohn s and Colitis · 124
PDF
The Frequency of Vitamin D Deficiency in Adults with Crohn’s Disease
2003 · Jesse S Siffledeen, Kerry Siminoski, et al. · Canadian Journal of Gastroenterology · 110
PDF
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
2021 · Silvio Danese, Jean-Frederic Colombel, et al. · ˜The œLancet. Gastroenterology & hepatology · 98
PDF
Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn’s disease
2005 · Jesse S. Siffledeen, Richard N. Fedorak, et al. · Clinical Gastroenterology and Hepatology · 76
PDF
Bones and Crohnʼs
2004 · Jesse S. Siffledeen, Richard N. Fedorak, et al. · Inflammatory Bowel Diseases · 76
PDF
Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case‐control study in the General Practice Research Database
2014 · Timothy R Card, Jesse Siffledeen, et al. · United European Gastroenterology Journal · 67
Vertebral Fractures and Role of Low Bone Mineral Density in Crohn’s Disease
2007 · Jesse S. Siffledeen, Kerry Siminoski, et al. · Clinical Gastroenterology and Hepatology · 49
A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease
2022 · Farhad Peerani, Makayla Watt, et al. · Therapeutic Advances in Gastroenterology · 35
An excess of prior irritable bowel syndrome diagnoses or treatments in Celiac disease: evidence of diagnostic delay
2013 · Timothy R. Card, Jesse Siffledeen, et al. · Scandinavian Journal of Gastroenterology · 32
Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure
2024 · Laurent Peyrin-Biroulet, Remo Panaccione, et al. · Clinical Gastroenterology and Hepatology · 30
Cendakimab in Adults and Adolescents with Eosinophilic Esophagitis
2025 · Evan S. Dellon, Christina M. Charriez, et al. · NEJM Evidence · 21
PDF
OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
2021 · S Danese, S Vermeire, et al. · Journal of Crohn s and Colitis · 19
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme
2011 · Marc Ferrante, Konstantinos Karmiris, et al. · Journal of Crohn s and Colitis · 18
Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial
2012 · Isaac Soo, Jesse Siffledeen, et al. · Journal of Crohn s and Colitis · 17
PDF
Effect of Suboptimal Disease Control on Patient Quality of Life: Real-World Data from the Observational IBD-PODCAST Canada Trial
2024 · Jesse Siffledeen, Sunny Singh, et al. · Digestive Diseases and Sciences · 15
PDF
Exploring Patient Perspectives on a 12-Week Online, Stress Reduction Intervention in Inflammatory Bowel Disease
2022 · Makayla Watt, Farhad Peerani, et al. · Crohn s & Colitis 360 · 6
PDF
OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics
2023 · L Peyrin-Biroulet, G Parkes, et al. · Journal of Crohn s and Colitis · 5
PDF
Long-Term Effectiveness and Safety of Ustekinumab Dose Escalation in Patients with Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study
2025 · Lisa M. A. van Lierop, Larissa Albino, et al. · Digestive Diseases and Sciences · 4
BioAdvance Patient Support Program Survey: Positive Perception of Intravenous Infusions of Infliximab.
2017 · Jennifer Jones, Mark Borgaonkar, et al. · PubMed · 4
Disease Monitoring in Inflammatory Bowel Disease Daily Clinical Practice and Impact on Treatment Decision Making: Real World Evidence From the Inflammatory Bowel Disease‐PODCAST Study
2025 · Axel Dignass, Fernando Magro, et al. · United European Gastroenterology Journal · 3
PDF
Treatment patterns for advanced therapies in Canadians with moderate-to-severe inflammatory bowel disease: a retrospective cohort analysis
2024 · Laura Targownik, Waqqas Afif, et al. · Journal of the Canadian Association of Gastroenterology · 3
PDF
Works count: 60
Citation count: 2,041
H-index: 17
I10-index: 19
Year
Topic
Type